Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Vaspin is highlighted as a novel adipokine that improves endothelium-dependent vasodilatation by inhibiting acetylcholine degradation, offering new insights into vascular regulation in obesity.
Vascular tone in the systemic circulation is regulated by the sympathetic innervation, circulating hormones and adaptation to transmural pressure, shear stress and metabolic factors. It is increasingly recognized that the surrounding perivascular tissue (PVT) also regulates tone development in conduit and resistance arteries by the release of soluble factors that mainly cause direct or indirect (e.g. endothelium-dependent) smooth muscle cell relaxation and hence lead to vasodilatation (Szasz & Webb 2012). Although the cause–effect relationship is still unclear, PVT – or the signalling between PVT and the arterial wall – has been found dysfunctional in cardiovascular disease (e.g. hypertension; Fasshauer & Bluher 2015, Li et al. 2013, Ozen et al. 2015), obesity (Greenstein et al. 2010, Aghamohammadzadeh et al. 2013) and inflammation (Bhattacharya et al. 2013). The high prevalence of obesity and type 2 diabetes – and the motivation to understand the mechanisms for development of cardiovascular complications in these patients – has centred research on signalling from perivascular adipose tissue to the vascular wall via bioactive molecules called adipokines. In the present volume of Acta Physiologica, a novel adipokine, vaspin, derived from visceral adipose tissue is proposed to augment acetylcholine-induced nitric oxide (NO)-mediated endothelium-dependent relaxations by inhibition of acetylcholine esterase activity (Kameshima et al. 2015). Adipokines signal from adipose tissue to other organs, and there is a persistent search for novel adipokines that may link obesity to related co-morbidities. Currently recognized adipokines include leptin, adiponectin, fibroblast growth factor 21 (FGF21), retinol-binding protein 4 (RBP4), dipeptidyl peptidase 4 (DPP-4), bone morphogenetic protein (BMP)-4, BMP-7, vaspin, apelin and progranulin (Fasshauer & Bluher 2015). The human vaspin protein consists of 415 amino acids, is member of the serine protease inhibitor family and has 40% homology with trypsin. Vaspin inhibits serine proteases by an irreversible suicide mechanism where an exposed reactive centre loop is presented to the target protease as a pseudosubstrate. A series of proteases – e.g. trypsin, elastase, collagenase and dipeptidyl peptidase – are not inhibited by vaspin (Hida et al. 2005), and until now the target proteases of vaspin have not been identified. Therefore, the finding by Kameshima et al. (2015) that vaspin inhibits acetylcholine esterase activity in the arterial wall is very interesting. As pointed out by the authors, however, it is pivotal to clarify whether vaspin acts by direct binding to a serine in the centre of the acetycholine esterase – as this may also imply regulation of other esterases in plasma – or by an indirect mechanism leading to altered acetylcholine esterase activity. To grasp the physiological importance of the acetylcholine esterase inhibition and the potentiated acetylcholine-induced vasodilatation by vaspin, it is also essential to understand the source of endogenous acetylcholine in the vascular wall. The mesenteric arteries investigated by Kameshima et al. mainly receive sympathetic innervation where noradrenaline, adenosine triphosphate and neuropeptide Y have been shown to mediate the vasoconstriction. Parasympathetic nerves have been reported mainly to release NO with sparse expression of the enzymes required for cholinergic transmission, whereas vasodilatory sensory nerves release calcitonin gene-related peptide (CGRP). The group of Burnstock et al. suggested the presence of choline acetyltransferase and release of acetylcholine from a non-neuronal source, the endothelial cells, in response to shear stress (Parnavelas et al. 1985). This was recently revisited, and release of acetylcholine from endothelial cells in rat aorta was found to play a role in vasodilatation induced by mild hypothermia (Zou et al. 2015). It was also suggested that activation of temperature-sensitive transient receptor potential (TRP) channels of different subtypes – e.g. TRPA1 and TRPV4 – leads to release of acetylcholine from endothelial cells (Zou et al. 2015). TRPV4 channels are also activated by shear stress, and based on these observations, it would be interesting to examine whether vaspin may enhance flow-mediated vasodilatation of mesenteric arteries by inhibition of the acetylcholine esterase. Lean adults have undetectable levels of vaspin in adipose tissue, but the vaspin mRNA expression increases markedly in obese individuals. In cardiovascular disease, concentrations of vaspin are low in patients who recently experienced a cerebral or coronary ischaemic event (Bluher 2012). Administration of recombinant vaspin improves glucose tolerance and insulin sensitivity in obese mice (Hida et al. 2005), inhibits endothelial cell apoptosis and prevents dysfunction of endothelial progenitor cells (Sun et al. 2015). The present findings suggest that vaspin can improve endothelium-dependent vasodilatation by inhibition of acetylcholine degradation, which adds to the beneficial effects of the protein. Therefore, vaspin is suggested as a potential biomarker and a basis for future pharmacological treatment strategies. Still, it remains to be addressed whether vaspin leads to enhanced vasodilatation in the atherosclerotic coronary circulation. A role for PVT in regulation of vascular tone was first suggested based on experiments with segments of rat aorta where the presence of PVT reduced noradrenaline-induced contractions (Soltis & Cassis 1991). In most in vitro experimental conditions, PVT is carefully removed as it is considered a diffusion hindrance to exogenously applied agonists. Therefore, the PVT-mediated vasomotor effects have been suggested to be overestimated (Li et al. 2013) or of minor significance (Bunker & Laughlin 2010). That the vascular wall indeed can possess a hindrance to exogenously applied vasoactive substances is known from balloon-mounted large arteries (Tanko et al. 1999) and studies comparing effects of drugs administered to the adventitial vs. luminal side of pressurized small arteries (e.g. Sun et al. 2001). However, in wire-mounted isometric preparations, the access of exogenous substances added to the lumen and the adventitia of the preparation is considered comparable. This is, however, only the case if there is thorough mixing of the solutions in the bath and/or the access to the arterial segment has been improved by removing some of the adhering PVT. The role of PVT has also been examined by placing it at the top of arteries – allowing for removal and reinstallation of the PVT – and by applying saline solutions incubated with PVT to arteries without PVT. Functionally, the preparation barrier can be tested by adding a direct smooth muscle dilator (e.g. the NO donor sodium nitroprusside) in the absence and presence of PVT. In the present study by Kameshima et al. (2015), an isometric microvascular myograph was used, and the PVT was carefully removed before the experiments. The authors find that vaspin inhibits acetylcholine esterase activity in the mesenteric arteries, whereas vaspin has no effect on the responses to vasoconstrictors or sodium nitroprusside. Further experimentation – including bioassay experiments, use of antibodies to capture vaspin or studies of mice genetically deficient in vaspin – will be required to couple adipose tissue-derived vaspin to regulation of vascular tone. The number of molecules proposed to mediate the vasodilatory effects of the PVT is rapidly increasing (Fig. 1) and currently includes prostaglandins (e.g. PGE2), H2S, leptin, NO, angiotensin 1–7 and adiponectin. Reactive oxygen species (e.g. superoxide) and inhibitory phosphorylation of the NO synthase have also been suggested to mediate vasocontractile effects of PVT (Ozen et al. 2015). In addition, the signalling pathways in the vascular smooth muscle cells underlying PVT-dependent vasodilatation have been explored; in some instances, the effect of PVT on the vascular smooth muscle cells has been found comparable to the effect of the candidate PVT-derived factor, while in other instances, contribution of still unknown PVT-derived factors has been proposed. The signalling mechanisms in the smooth muscle cells often involve hyperpolarization attributed to opening of a variety of K+ channels (e.g. ATP-sensitive and voltage-dependent K+ channels; Galvez et al. 2006), but recently activation of smooth muscle calcium-desensitizing mechanisms (e.g. inhibition of myosin light chain phosphatase phosphorylation) has also been described (Aalbaek et al. 2015). In addition to leptin and adiponectin, vaspin is the third adipokine suggested to regulate vascular tone. However, other adipokines (e.g. visfatin) have been found to inhibit endothelium-dependent vasodilatation (Vallejo et al. 2011), and it remains to be investigated how altered secretion of adipokines affects the regulation of vascular tone, structural remodelling of arteries and the development of vascular complications associated with obesity and type 2 diabetes. In summary, the study by Kameshima et al. (2015) reveals a new adipokine, vaspin, which inhibits acetylcholine degradation and hence leads to vasodilatation. The study proposes acetylcholine esterase as a potential new target for vaspin, and although evidence for direct regulation of the acetylcholine esterase is still lacking, the reported findings raise interesting perspectives for cardiovascular disease and other complications associated with obesity. The authors have no conflict of interest to declare.
No takes yet. Share an insight, caveat, or question.
Simonsen et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: